An ontological foundation for ocular phenotypes and rare eye diseases
- 1.3k Downloads
The optical accessibility of the eye and technological advances in ophthalmic diagnostics have put ophthalmology at the forefront of data-driven medicine. The focus of this study is rare eye disorders, a group of conditions whose clinical heterogeneity and geographic dispersion make data-driven, evidence-based practice particularly challenging. Inter-institutional collaboration and information sharing is crucial but the lack of standardised terminology poses an important barrier. Ontologies are computational tools that include sets of vocabulary terms arranged in hierarchical structures. They can be used to provide robust terminology standards and to enhance data interoperability. Here, we discuss the development of the ophthalmology-related component of two well-established biomedical ontologies, the Human Phenotype Ontology (HPO; includes signs, symptoms and investigation findings) and the Orphanet Rare Disease Ontology (ORDO; includes rare disease nomenclature/nosology).
A variety of approaches were used including automated matching to existing resources and extensive manual curation. To achieve the latter, a study group including clinicians, patient representatives and ontology developers from 17 countries was formed. A broad range of terms was discussed and validated during a dedicated workshop attended by 60 members of the group.
A comprehensive, structured and well-defined set of terms has been agreed on including 1106 terms relating to ocular phenotypes (HPO) and 1202 terms relating to rare eye disease nomenclature (ORDO). These terms and their relevant annotations can be accessed in http://www.human-phenotype-ontology.org/ and http://www.orpha.net/; comments, corrections, suggestions and requests for new terms can be made through these websites. This is an ongoing, community-driven endeavour and both HPO and ORDO are regularly updated.
To our knowledge, this is the first effort of such scale to provide terminology standards for the rare eye disease community. We hope that this work will not only improve coding and standardise information exchange in clinical care and research, but also it will catalyse the transition to an evidence-based precision ophthalmology paradigm.
KeywordsEvidence-based precision medicine Rare eye disease Human phenotype ontology Orphanet rare disease ontology
Electronic healthcare record
European Reference Network on rare eye diseases
Human Phenotype Ontology
International Statistical Classification of Diseases and Related Health Problems
Online Mendelian Inheritance in Man
Orphanet Rare Disease Ontology
rare eye disease
Systematized Nomenclature of Medicine-Clinical Terms
Rare eye diseases (REDs) are a major cause of visual impairment and blindness in children and young adults [1, 2]. To date, according to Orphanet, over 1000 REDs have been described; the majority of these conditions are genetic and many of them have prominent extraocular features . Although each individual disorder is rare (defined in the European Union as affecting less than 1 in 2000 individuals ), collectively they are common and their cumulative impact on affected families and healthcare systems is substantial [5, 6].
The rarity of each RED, together with the significant clinical and genetic heterogeneity that characterises this group of conditions, can make precise diagnosis and evidence-based management challenging. To improve patient care and to obtain sufficient sample sizes for research, responsible sharing of knowledge and data across centres and countries is required . Adoption of comprehensive phenotype and rare disease ontologies enables this type of sharing by making data findable, accessible, interoperable, and re-usable (FAIR principles) .
This work focuses on developing the ophthalmology-related component of two widely utilized biomedical ontologies, the Human Phenotype Ontology (HPO) and the Orphanet Rare Disease Ontology (ORDO) [3, 10, 12, 13]. Each term in HPO describes a distinct phenotypic feature such as a symptom (e.g. photophobia) or a sign (e.g. Haab’s striae), while each ORDO term corresponds to a specific rare disorder (e.g. posterior polymorphous corneal dystrophy).
To set a robust ontological foundation for ocular phenotypes and REDs a multi-step approach was utilized. The HPO project commenced in 2007 with the initial aim of aiding rare disease phenotyping and diagnostics . Data from the Online Mendelian Inheritance in Man (OMIM; https://omim.org/) database were used for the construction of HPO and, over the past decade, significant refinement and expansion occurred through manual curation and careful mapping to other resources including the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT; https://www.snomed.org/snomed-ct) and the International Statistical Classification of Diseases and Related Health Problems (ICD; http://www.who.int/classifications/icd/). The latest release of HPO (11/2018) includes 1106 terms related to ocular phenotypes. There are 842 textual and/or logical definitions and 968 synonyms related to these terms; 1208 subclass relationships and 7702 annotations of ocular phenotypes to 2770 rare disorders have been created. A set of tools that can be used to explore HPO can be found in https://hpo.jax.org/app/tools/hpo-browser and https://hpo.jax.org/app/tools/workbench.
Orphanet is an international data resource that was created in 1997 to address the scarcity and fragmentation of information on rare diseases. This unique database has grown substantially over the past 20 years by incorporating expert advice and through extensive manual curation of medical literature. Importantly, there is almost complete linkage of Orphanet with SNOMED-CT and ICD, two resources that are commonly used in electronic healthcare records (EHRs) but are presently less rich in rare disease related content. The Orphanet nomenclature evolved into a formal ontology (ORDO) in 2014 and the latest version (11/2018) includes 1202 RED-related entries (including 146 groups, 834 disorders and 222 subtypes) each having a unique, stable ORPHA number. The Orphanet nomenclature can be browsed in https://www.orpha.net and ORDO is available at http://www.orphadata.org/cgi-bin/index.php#ontologies.
Our efforts to enrich the ophthalmology-related content of these two resources culminated in a 4-day workshop in October 2017 (ERN-EYE Ontology meeting, Mont Sainte-Odile, France). In this meeting, 60 members of the European Reference Network on rare eye diseases (ERN-EYE) from 29 centres of 13 countries  worked with international experts to enrich the HPO and Orphanet classifications and to agree on a broad range of terms. Briefly, the adopted approach involved sharing existing HPO terms and Orphanet classifications with all ERN-EYE members prior to the workshop. Participants were distributed in six working groups (retina, neuro-ophthalmology, paediatric ophthalmology, anterior segment, low vision, and genetic diagnostics) who discussed issues and suggestions. Patient representatives were also consulted and their active participation at the workshop provided key insights. Subsequent engagement of ERN-EYE members has led to further refinement of the ontologies including providing definitions and other relevant annotations. Overall, 605 new HPO terms related to ocular disease were added and over 400 terms were revised (including adding definitions and/or synonyms, correcting errors and removing/merging obsolete terms). The Orphanet classification was fully restructured with more than 67 groups created, 36 disorders introduced, 90 entities removed/merged, and 131 modifications made in the nomenclature. For further information on the specific changes made as a result of the workshop please see Additional file 1: Tables S1 and S2.
There are multiple advantages in using ontologies, the most important one being enhanced data integration: by making data computationally accessible it is possible to bridge the compatibility gap between different healthcare systems, databases and languages. Also, sophisticated cross-resource bioinformatics analyses with data from other domains (e.g. genomic data) is enabled. These features have made ORPHA numbers a standard for rare disease coding in European healthcare systems and have led to the widespread adoption of ontologies like HPO by global genomics initiatives (e.g. Matchmaker Exchange  and RD-Connect ) and clinical genetic laboratories. Notably, both ORDO and HPO are open-access, interoperable, community-driven, available in multiple languages and regularly updated (twice a year for ORDO, at least quarterly for HPO). Requests for new terms or other amendments can be made through the Orphanet and HPO portals and we hope to engage all stakeholders in this ongoing effort. The ERN-EYE remains committed to further improving these resources and future plans include working on “layperson” terms for ocular phenotypes (so that patients can also use HPO) and on annotating each RED with HPO terms (to enhance diagnostic accuracy) .
To our knowledge, this is the first effort of such scale to provide terminology standards for the RED community. The resources outlined in this article have the potential to transform both routine care (e.g. by integration in EHRs) and research (e.g. recording clinical data in registries) for RED. We believe that collaborative efforts like this not only result in improved data classification and coding, but also lead to growing acceptance of standard nomenclatures among the RED community. Finally, we hope that this work will catalyse responsible inter-institutional data sharing and facilitate the transition to an evidence-based precision medicine paradigm for RED .
ERN-EYE Ontology Study Group: Jane L. Ashworth (Manchester Royal Eye Hospital, Manchester, UK), Isabelle Audo (Quinze-Vingts National Ophthalmology Hospital, Paris, France), Vilma Jurate Balciuniene (Hospital of Lithuanian University of Health Science, Kaunas, Lithuania), Eyal Banin (Hadassah Medical Center, Jerusalem, Israel), Graeme C. Black (University of Manchester, Manchester, UK), Daniel Böhringer (Eye Centre, University Hospital Freiburg, Germany), Camiel J.F. Boon (Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; Leiden University Medical Center, Leiden, the Netherlands), Dominique Bremond-Gignac (University Hospital Necker-Enfants Malades, Paris, France), Patrick Calvas (University of Toulouse, Toulouse, France), Guilherme Castela (University of Coimbra, Coimbra, Portugal), Gislin Dagnelie (Johns Hopkins University School of Medicine, Baltimore, USA), Hélène Dollfus (Strasbourg University Hospital, Strasbourg, France), Susan M. Downes (Nuffield Department of Clinical Neuroscience, John Radcliffe Hospital, Oxford, UK), Adriano Fasolo (The Veneto Eye Bank Foundation, Venice, Italy), Christina Fasser (Retina International, Zürich, Switzerland), Arvydas Gelzinis (Hospital of the Lithuanian University of Health Science, Kaunas, Lithuania), Kerry Goetz (National Eye Institute, Bethesda, USA), Steffen Hamann (Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Glostrup, Denmark), Elise Héon (The Hospital for Sick Children, Toronto, Canada), Giancarlo Iarossi (Bambino Gesù Children’s Hospital, Rome, Italy), Aki Kawasaki (University of Lausanne, Lausanne, Switzerland), David Keegan (Mater Misericordiae University Hospital, Dublin, Ireland), Line Kessel (Glostrup Hospital, University of Copenhagen, Glostrup, Denmark), Kamron Khan (St James’s University Hospital, Leeds, UK), Artur Klett (Eye Clinic of East Tallinn Central Hospital, Tallinn, Estonia), Sebastian Köhler (Charité-Universitätsmedizin Berlin, Berlin, Germany), Dorothée Leroux (Strasbourg University Hospital, Strasbourg, France), Bart P. Leroy (Ghent University & Ghent University Hospital, Ghent, Belgium), Walter Lisch (Johannes Gutenberg University Mainz, Mainz, Germany), Petra Liskova (Charles University & General University Hospital in Prague, Prague, Czech Republic), Birgit Lorenz (Justus Liebig University, Giessen, Germany), Riccardo Maggi (Bambino Gesù Children’s Hospital, Rome, Italy), Emmanuel Maxime (Orphanet, INSERM, Paris, France), Isabelle Meunier (University of Montpellier, Montpellier, France), Saddek Mohand-Said (Quinze-Vingts National Ophthalmology Hospital, Paris, France), Katarzyna Nowomiejska (Medical University of Lublin, Lublin, Poland), Yaumara Perdomo (Strasbourg University Hospital, Strasbourg, France), Axel Petzold (Moorfields Eye Hospital, London, UK), Markus Preising (Justus Liebig University, Giessen, Germany), Peter N. Robinson (The Jackson Laboratory for Genomic Medicine, Farmington, USA), Hendrik P.N. Scholl (Institute of Molecular & Clinical Ophthalmology Basel, Basel, Switzerland; Department of Ophthalmology, University of Basel, Basel, Switzerland; Wilmer Eye Institute, Johns Hopkins University, Baltimore, United States), Panagiotis I. Sergouniotis (University of Manchester, Manchester, UK), Andrea Sodi (Careggi Teaching Hospital, Florence, Italy), Katarina Stingl (University of Tübingen, Tübingen, Germany), Fouzia Studer (Strasbourg University Hospital, Strasbourg, France), Agnese Suppiej (Pediatric University Hospital of Padova, Italy), Rachel Thompson (Newcastle University, Newcastle upon Tyne, UK), Valerie Touitou (Pitie-Salpetriere Hospital, Paris, France), Elias Traboulsi (Cleveland Clinic, Cleveland, USA), Jurgis Trumpaitis (Hospital of Lithuanian University of Health Science, Kaunas, Lithuania), Stephen J. Tuft (Moorfields Eye Hospital, London, UK), Veronika Vaclavik (Jules-Gonin Eye Hospital, Lausanne, Switzerland), Sandra Valeina (Children’s Clinical University Hospital, Riga, Latvia), Caroline Van Cauwenbergh (Ghent University & Ghent University Hospital, Ghent, Belgium), Alain Verloes (APHP - University Hospital Robert Debré, Paris, France), Alain Vighetto (Hospital for Neurology & Neurosurgery Pierre Wertheimer, Bron, France), Russell Wheeler (Leber’s Hereditary Optic Neuropathy (LHON) Society, UK), Thomas Wheeler-Schilling (University of Tübingen, Tübingen, Germany), Patrick Yu-Wai-Man (University of Cambridge, Cambridge, UK; Moorfields Eye Hospital, London, UK), Ditta Zobor (University of Tübingen, Tübingen, Germany), Eberhart Zrenner (University of Tübingen, Tübingen, Germany). This list can also be also found in the Additional file.
This work was supported by the ERN-EYE project which is co-funded by the Health Program of the European Union under the Framework Partnership Agreement #739534 — ‘ERN-EYE’. We also acknowledge the following sources of funding: National Institutes of Health (NIH) [Monarch Initiative] (NIH OD #5R24OD011883); French Directorate General for Health and European Commission Directorate-General for Health and Consumers (Orphanet Europe Joint Action Grant #20102206 and Orphanet Operating Grant #20133305-INSERM_FY2014); European Commission [RD-Connect] (Grant #305444); UK National Institute of Health Research (NIHR) Clinical Lecturer Programme [PIS]. The funders had no role in the design and conduct of the study and the authors declare no conflict of interest.
Availability of data and materials
The datasets generated and/or analysed during the current study are available in the relevant HPO and Orphanet repositories, ttp://www.orphadata.org/cgi-bin/index.php#ontologies and http://www.orpha.net.
Conception and design: PIS, AR, PNR, HD. Data collection and analysis: PIS, EM, DL, AO, AR, PNR, HD. Data review: all authors (including all ERN-EYE Ontology Study Group members). Obtained funding: AR, PNR, HD. PIS wrote the manuscript and all other authors (including all ERN-EYE Ontology Study Group members) critically revised and edited the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 3.Orphanet, an online database of rare diseases and orphan drugs. 1997. http://www.orpha.net. Accessed 05 Sep 2018.
- 4.The European Parliament and the Council of the European Union (1999). Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf.Google Scholar
- 8.Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The FAIR guiding principles for scientific data management and stewardship. Sci Data. 2016;160018:3.Google Scholar
- 10.Haendel M, McMurry J, Relevo R, Mungall C, Robinson P, Chute PC. A census of disease ontologies. Annu Rev Biomed Data Sci. 2018; https://doi.org/10.1146/annurev-biodatasci-080917-013459.CrossRefGoogle Scholar
- 14.ERN-EYE, a European Reference Network dedicated to Rare Eye Diseases. 2017. https://www.ern-eye.eu/. Accessed 05 Sep 2018.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.